RxDoctor Payments Data

Sanjay Chaudhuri, MD

Psychiatry · Monroe, LANPI 1548879877

Payments from drug & device makers

$2,422in general payments, 2019–2025

Across 109 payments — averaging $22.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$393
  • AbbVie$366
  • Axsome Therapeutics, Inc.$334
  • Alkermes, Inc.$314
  • Otsuka America Pharmaceutical, Inc.$271
  • Johnson & Johnson$177
  • plus $568 from 6 others

What the payments were for

  • Food & beverage$2,419100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,422 in reported general payments places this provider in the 75th percentile of 474 psychiatry providers in Louisiana.

See all psychiatry providers in Louisiana

Medicare billing

Part B allowed, 2024
$11,569
Medicare patients
37
Services billed
156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl14$21,541
Lurasidone Hcl11$3,348
Bupropion XlBupropion Hcl60$1,253
Mirtazapine71$1,166
Divalproex Sodium ErDivalproex Sodium35$1,109
Trazodone Hcl85$910
Venlafaxine Hcl ErVenlafaxine Hcl77$863
Buspirone Hcl58$854
Duloxetine Hcl41$841
Quetiapine Fumarate53$710
Aripiprazole38$593
Prazosin Hcl19$445
Hydroxyzine Hcl36$411
Sertraline Hcl39$321
Risperidone16$256

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$366$21,54114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 474 psychiatry providers in Louisiana.

Other psychiatry in Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →